IDH1 and acute myeloid leukemia: For older t‐AML patients and young patients with comorbidities not eligible for IC and/or Allo‐HCT, HMA or cytarabine associated to venetoclax with or without targeted therapies (FLT3, IDH inhibitors, or anti‐CD47 antibody especially for TP53 mutated patients) seems to be the best therapeutic option.